Immuno-Oncology Xchange West Coast 2019
Immune Biomarkers
- What emerging predictive biomarkers have the potential to be disruptive in the current clinical setting?
- Will less invasive biomarkers (e.g. ctDNA, other blood-based biomarkers) overtake and displace tumor tissue-based predictive biomarkers in the I-O clinical space?
- What challenges do you see with multiple biomarkers being utilized in the I-O clinical space? Is there a role to use multiple biomarkers even in monotherapy treatment?
- Beyond predictive biomarkers for anti-PD1 monotherapy, what is the strategy to predict response to combination therapies? Will multiple biomarkers be necessary to appropriately identify patients most likely to benefit from various combination therapies?
- What is the relative role for assessing exploratory/mechanistic biomarkers in a clinical trial vs. primary, formal biomarkers on a regulatory path to CoDx development (e.g. patient segmentation listed on the label)?
Executive Director, Profiling & Expression, Translational Medicine
Merck
Terri McClanahan is currently the Executive Director of the Profiling & Expression group in Translational Medicine at Merck Research Laboratories. Her group combines multiple molecular, cellular and tissue-based approaches to interrogate disease mechanisms, working closely with discovery biologists and drug development teams to provide mechanistic data, disease association and biomarkers of drug response. She oversees and integrates the work of several key areas utilizing multiple tissue-based methodologies including histopathology, flow cytometry, cell sorting and molecular profiling, to support projects spanning from the earliest novel discovery projects to IND-enabling mechanistic studies, tissue, cell type and disease tissue expression profiling, and translational biomarker discovery, with a specific emphasis on immune regulation and immune-oncology.
- Monitoring changes in patient cancer in realtime
- Patient comfort and ease of frequent diagnosis through liquid biopsies
- Technical challenges in isolation of exosomal vesicles
- Challenges in validation, identification of function and profile
- Confluence of advanced analytical methods such as multiplexed proteomics, sequencing, PCR, cell-based assays and other method
Chief Executive Officer
MD Bioscience
Eddie Moradian received his PhD in biotechnology from the Swiss Federal Institute in Zurich, Switzerland. Since 1987, he has been a founder or co-founder of a series of companies in the biotechnological, pharmaceutical and diagnostic industries with presence in Europe, US and Israel. At MD Biosciences, he leads a global group of companies founded in 1991, each individually focused on drug development, preclinical contract research services and CLIA clinical biomarker diagnostic development and analysis services.
- How to design tangible and effective biomarker testing plans – Schedule of assessment, sample collection scheme, and sample types – Platform and vendor selection
- How to properly control sample quality and pre-analytical factors
– Sample collection methods and sample quality
– Challenges in operations and communication - Challenges of analyzing biomarker testing data – Resources for bioinformatics
– Integration of clinical data
Director, Clinical Biomarkers
Calithera Biosciences
Yu Liang is the Director of Clinical Biomarkers at Calithera Biosciences with over 17 years of technical expertise and strategic leadership from both academic and industry in application of genomic and genetic profiling for biomarker discovery, development of real-time PCR assays for research and IVD, and implementation of biomarker programs to support all phases of drug development pipelines. Yu currently is focusing on targeting arginase and glutaminase, and in combination with immune checkpoint inhibitors. He managed biomarker portfolios of Ibrutinib at Pharmacyclics. Prior to that, he led development and applications of most TaqMan small RNA assays at Applied Biosystems and Life Technologies.
- Autologous vs allogenic – what, who and how? Applications, manufacturing, and personalization of cellular and genetic therapeutics
- Cost management – what does the industry look like in 5 years? 10 years?
- Blurring lines – how do the “engineering” challenges of cell and gene therapies compete with the clinical challenges? Which is greater?
Vice President, Business Development
Synthego
Jason Steiner is the VP of Business Development at Synthego and directs strategy and technical partnerships that leverage Synthego’s platform technologies in genome engineering, machine learning, and automation engineering to accelerate life science research and discovery applications. Prior to Synthego, Jason spent several years in the clinical genomics space commercializing liquid biopsy technologies and applications in both reproductive genetics and oncology. Jason holds a doctoral degree in Biotechnology and Biomedical Engineering from the University of California, San Diego where his research focused on the development of nanoparticle delivery systems for therapeutic and diagnostic payloads to tumors.
Translational Research
- Which types of pre-clinical data have the strongest impact on your confidence that a new IO molecule will perform as expected in the clinic? (efficacy, toxicity)
- What is the relative value of data coming from in vitro studies vs. animal studies for IO therapies?
- Does the balance shift based on type of molecule, biological target, or target indication?
- Which in vitro systems provide the most clinically relevant data?
- Which animal models provide the most clinically relevant data?
- What set(s) of circumstances would lead you to decide that animal model data is not relevant or not required for a pre-clinical data package?
Antibody Therapeutics Expert
Shelley Force Aldred recently served as VP for Preclinical Development at TeneoBio where she led the preclinical efforts creating a CD3xBCMA bispecific antibody, from product concept to IND-ready package. Shelley was formerly director of R&D for Active Motif following the acquisition of SwitchGear Genomics in 2013. In 2006, she co-founded SwitchGear Genomics and she served as its COO. Prior to founding SwitchGear Genomics, Shelley was a Scientific Director on Stanford’s ENCODE Project and received her Ph.D. from Stanford University.
- How to discover and select meaningful biomarkers to inform combination strategies?
- Learning from previous clinical studies to direct future combination trials (“from the bench to the bedside and back to the bench”)
- How do we gain confidence in clinical success of a particular combination from translational models
Director, Translational Applications
Farcast Biosciences
Mark Paris is the technical lead for Farcast Biosciences’ marketing effort and works with biopharma organizations to craft custom solutions for their drug development needs. He spent 16 years in
commercial antibody discovery and clinical development focusing on immuno-oncology. Molecules discovered and developed under his direction are currently in Phase 2 clinical trials. Mark is a
graduate of Case Western Reserve University with a PhD in Genetics, and a former fellow in the department of Cancer Biology at the Cleveland Clinic Foundation.
- Utility of syngeneic models to evaluate IO drug therapeutic efficacy and combination strategies
- Challenges associated with humanized mouse tumor models to recapitulate human tumor immune biology and relevance to translation to clinical responses with IO therapeutics
- How well do genetically engineered mouse models translate to clinical responses ?
Vice President, Immuno-Oncology
IGM Biosciences
Angus Sinclair PhD is the Vice President Immuno-oncology Research at IGM Biosciences Inc with over 16 yrs experience in the biotech industry. Prior to joining IGM Biosciences, Angus was the Senior Director of Oncology at Northern Biologics Inc, Toronto and Scientific Director of Oncology at Amgen. During his tenure in biotech, Angus has progressed multiple antibody-based and small molecule therapeutics through preclinical research and development to the clinic. Before joining Amgen, Angus held academic positions at UT Southwestern Medical Center, Texas; University of Cambridge, UK and UCSD, California.
- How can we target tumor intrinsic properties to maximize an IO response?
- Do specific oncogenic mutations determine the immune landscape in the tumor microenvironment and therefore will determine success of immunotherapy? Can we model this in a mouse?
- How to choose mouse models to test combinations of targeted therapy with Immuno-modulatory agents? Do we have enough options?
- Can genetically engineered mouse models of cancer reveal new insights about the antitumor immune response?
- Are there ways to make genetically engineered mouse models of cancer more immunogenic?
Head of Immuno-Oncology
Revolution Medicines
Elsa is a Pharmacologist with over 15 years of experience in cancer biology and immuno-oncology. Highly experienced in human and murine tumor models for the evaluation of novel oncology and immune-oncology agents. Before joining Revolution Medicines, she was at Oncomed Pharmaceuticals leading cancer stem cell and immuno-oncology programs. During her postdoct at the University of Michigan, Elsa completed seminal work on tumorigenesis and metastasis in melanoma. Author of over 20 publications in peer-reviewed journals including first author articles in Nature, Cancer Cell and Science Translational Medicine. Elsa received her Ph.D. in Pharmacology from University of Valencia, Spain.
Clinical Trials
- Does IL increase immunogenicity?
- How to measure tumor immunogenicity?
- Do epigenetics have a role in immunogenicity?
- How does CTL4 plus Nivo and CTL4 plus Pembro work?
- How successful are IOs in aggressive malignancies such as GI?
Vice President, Oncology Clinical Development
HUYA Bioscience
Mann Muhsin has been practicing physician for over 20 years with more than 13 years in Clinical Research and more than 7 years of Medical Practice in Civilian and US Army Medical Corps Hospitals.
Mann has held positions of increasing responsibility in Clinical Development at Janssen, the pharmaceutical division of Johnson and Johnson, Halozyme, OncoSec, UCSD, and other companies and CRO where he led multi-phase sponsored trials for: Lilly, Astra Zeneca, Merck, Novartis, Hoffmann La Roche, Amylin, DexCom, Biodel, Medtronic, ResMed and Bayer. He has extensive experience in immuno-oncology, he led Clinical Collaborations with Merck’ Pembrolizumab, Genentech’s Atezolizumab, IL-12, and other IO agents.
- What types of questions can be answered using primary immune cells?
- What are the challenges of working with primary immune cells?
- What types of immunotherapeutic products have been assessed using these methods?
Founder & Chief Technology Officer
ImmunXperts
Sofie has over 20 years of experience in the field of immunogenicity assessment (vaccines and biotherapeutics). She has extensive hands-on lab experience and has managed and coached several In Vitro teams over the last decade. From 2008 till 2013 she was Head of the In Vitro Immunogenicity group at AlgoNomics (Ghent, Belgium) and Lonza Applied Protein Services (Cambridge, UK). Prior to that, she worked at Innogenetics, Belgium for over 15 years.
- What are the pathways of immune resistance?
- How can one enrich the right patient popoulation early during clinical development?
- What are possible combination trials to address the immune resistance mechanisms?
Senior Vice President, Biology,
RAPT Therapeutics
Dirk Brockstedt is Senior Vice President of Biology and has more than 20 years of experience in the fields of immunology and oncology originating with his PhD from the University of Kiel and Stanford University. Dirk joined RAPT Therapeutics in January 2018, bringing a wealth of experience in immunology at all stages of discovery, translational and clinical development. He joined RAPT from Aduro Biotech, where he served as Executive Vice President of Research and Development. Prior to Aduro, Dirk held positions of increasing responsibility within the immunology department of Cerus Corporation and at Aventis in the immunotherapy and anti-angiogenesis groups. Dr. Brockstedt co-authored over 40 scientific papers and is a named inventor on seven issued patents and several pending applications.
- What are the biggest challenges in I/O R&D where mathematical modeling could help?
- What types of questions can we answer with the help of mathematical modeling?
- Where is the biggest ROI for incorporating mathematical modeling into an I/O program?
Co-Founder, President & Chief Executive Officer
Applied Biomath
John Burke received his PhD in Applied Mathematics from Arizona State University, and his BS and MS in Applied Mathematics from the University of Massachusetts, Lowell. Prior to co-founding Applied BioMath, John was at Boehringer Ingelheim as Associate Director, Head of Systems Biology and promoted to Senior Principal Scientist. John has also held positions at Merrimack Pharmaceuticals, the Systems Biology Department at Harvard Medical School, and in Douglas A. Lauffenburger’s lab at MIT.
Targeted Immunotherapies
- How to address the challenges of finding TCR targets?
- How to monitor changes in TCR specificity during TCR engineering?
- Best ways to identify endogenous TCRs with optimal anti-tumor activities?
- Impact of HLA restriction on patient populations: need for diagnostics?
- Will HLA and target downregulation limit the durability of responses?
Senior Vice President & Chief Scientific Officer
3T Biosciences
Hans-Peter has over 20 years of research and development experience in oncology, including antibody-drug conjugates (ADCs), redirected T-cell targeting compounds and adoptive T-cell therapies. He has been leading Pfizer’s Bioconjugates division as CSO, overseeing Pfizer’ s efforts in ADC, redirected T-cell targeting and nanoparticle development. He previously held senior leadership positions at Seattle Genetics and Genentech. Hans-Peter is currently CSO and Senior Vice President at 3T Biosciences, where he is overseeing platform- and therapeutic program development of TCR-T, TCR mimetic antibodies and cancer vaccine therapeutics. He is a recognized leader in oncology drug development, spanning from target identification and validation, development of novel therapeutic modalities and companion diagnostics, regulatory filings and translational support for early clinical development. He has a proven track record in making initial contacts and to successfully execute external collaborations and licensing deals with academia and corporate partners.
- How do organoids fit in as an in vitro screening tool ?
- Utility of using organoids in the IO space: advantages/limitations?
- What is the impact of the organoid platform on the relevance of PDX studies?
General Manager, San Diego
Crown Bioscience
Jayant is an Immunologist with 22 years of post-PhD research experience in the academia and industry in areas of cancer, autoimmunity, inflammation and pain. At Arena Pharmaceuticals he successfully
championed two drug discovery programs that identified two NCEs(currently in Ph II and Ph III trials) that target GPCRs from hit-to-lead up to pre-clinical development. As Director of R&D and Associate Director of Operations at Molecular Response, his pharmacology team successfully completed numerous client
projects that significantly increased revenue growth for the company, which ultimately resulted in the acquisition of the PDX business by Crown Bioscience. As Director of Operations at Crown Bioscience San Diego, he successfully developed several platforms including PDX models, syngeneic and humanized PDX
platforms to support immuno-oncology projects for clients. He is currently the General Manager at Crown Bioscience San Diego. Jayant did his PhD from the National Institute of Immunology in New Delhi India, followed by post-doctoral research at UT Southwestern Medical Center at Dallas and the University of Virginia at Charlottesville.
Co-Founder & Chief Scientific Officer
Fount Therapeutics
- The number of “clinically validated” tumor targets is relatively small so where are the next generation of targets coming from?
- How do we validate novel tumor-specific targets given the process can be very resource intensive?
- New therapeutic modalities such as CART and CD3 bispecific engagers require very restricted patterns of target expression so what tools/platforms/models do we need to help bring these “next generation” therapeutics to the clinic?
Chief Scientififc Officer & Senior Vice President
Atreca
Norman Greenberg leads a multi-disciplinary research and development team that is delivering unique therapeutics based on anti-cancer antibodies identified from the immune repertoires of elite responder patients in multiple indications. During his career in Pharma and Biotech, Norman was Senior Vice President for Translational Medicine at Checkmate Pharmaceuticals supporting an innovative CpG based therapy, Vice President of Global Oncology Research at MedImmune/AstraZeneca where his group delivered therapeutics against PDL1, OX40 and other targets and Senior Director of Oncology Research at Pfizer where his group helped deliver a therapeutic targeting 41BB. As an academic, he was a Full Member at the Fred Hutchinson Cancer Research Center in Seattle and a Tenured Professor at Baylor College of Medicine in Houston. Norman has been widely recognized for his early work creating the genetically engineered TRAMP mouse model for prostate cancer and demonstrating the oncogenic potential of mutated androgen receptors.Norman Greenberg leads a multi-disciplinary research and development team that is delivering unique therapeutics based on anti-cancer antibodies identified from the immune repertoires of elite responder patients in multiple indications. During his career in Pharma and Biotech, Norman was Senior Vice President for Translational Medicine at Checkmate Pharmaceuticals supporting an innovative CpG based therapy, Vice President of Global Oncology Research at MedImmune/AstraZeneca where his group delivered therapeutics against PDL1, OX40 and other targets and Senior Director of Oncology Research at Pfizer where his group helped deliver a therapeutic targeting 41BB. As an academic, he was a Full Member at the Fred Hutchinson Cancer Research Center in Seattle and a Tenured Professor at Baylor College of Medicine in Houston. Norman has been widely recognized for his early work creating the genetically engineered TRAMP mouse model for prostate cancer and demonstrating the oncogenic potential of mutated androgen receptors.
Combination Therapies
- What are the critical considerations for I-O combination clinical studies?
- How to execute I-O combination trials in a competitive environment?
- How important is it to show single agent activity before launching combination studies?
President & Chief Executive Officer
Apexigen
Xiaodong Yang is the founder, CEO and a member of the board of directors. Prior to forming Apexigen, he served as Vice President of Research and Preclinical Development at Intradigm Corporation (now Silence Therapeutics). Xiaodong began his career as a founding scientist at Abgenix, Inc. (now Amgen) where he was Senior Director and headed the Oncology Therapeutic Program Team responsible for setting strategy and managing the company’s oncology portfolio. While at Abgenix he served as the project team leader for Vectibix® (panitumumab) and played a key role in its discovery, development and BLA approval. Xiaodong also led Abgenix’s partnerships on a number of therapeutic antibody collaboration programs.
- How can the challenges of integrating sample phenotype data with sample genotypic information be overcome?
- How do you identify where the samples are in your research workflows?
- What strategies can be implemented to integrate sample location data with the sample analysis and quality data?
- How do you address the difficulties of integrating the data and meta-data between wet lab and dry lab (analysis)?
President & Chief Executive Officer
L7 Informatics
- IO naïve patients with immune-refractory tumors vs treatment failures from immune-responsive indications: which is a better choice for seeking efficacy signals?
- Biomarkers for patient and indication selection: what’s the best use of prospective vs retrospective biomarker assessment in confirming existing indications or selecting future indications?
- How to evaluate the possible effect of prior lines of therapy on the efficacy of your combination?
Chief Scientific Officer
Compugen
John Hunter joined Compugen in April 2012 as Vice President, Antibody R&D and US Site Head, and was appointed Chief Scientific Officer in April 2018. At Compugen he established the US subsidiary drug development unit of the company, and oversaw the advancement of three programs from concept to IND. Prior to joining Compugen, John served as a Senior Director at XOMA, managing strategic and functional activities related to building a robust preclinical antibody pipeline. He began his industry career at Millennium Pharmaceuticals, where he specialized in oncology therapeutics research. John holds a B.A. in Biology from Hartwick College and a Ph.D. in Immunology from the University of California San Francisco.
- How are big pharma and small biotech approaching this? What is truly unique about the drug a company is developing?
- Find the right combination of molecule, technology platform for the IO target(s)
- How important is it to invest effort upfront in research to finding biomarkers to predict patient responses which will help in getting to clinical POC faster?
Executive Director, Biotherapeutics
Exelixis
Seema Kantak is currently Executive Director, Biotherapeutics at Exelixis where she is leading the oncology biotherapeutics external R&D effort, focusing on the identification, evaluation and early development of biologics assets and is responsible for establishing, building and advancing a biotherapeutics portfolio. Prior to Exelixis she was Chief Scientific Officer at a start-up, Symic Bio. Prior to joining Symic, Seema held leadership positions at Nektar Therapeutics, XOMA, Celera Therapeutics and Axys Pharmaceuticals. Seema has contributed to several IND submissions in multiple therapeutic areas. She received her Ph.D. in Cancer Biology from Wayne State University School of Medicine, and completed her postdoctoral work at UCSF. Dr. Kantak also holds a M.S. in Biology from Wayne State University and a M.S. in Biophysics from Bombay University.